Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended			1 Months Ended	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended	6 Months Ended					6 Months Ended					0 Months Ended	3 Months Ended	1 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended	1 Months Ended		0 Months Ended	1 Months Ended	3 Months Ended	1 Months Ended	3 Months Ended	6 Months Ended		0 Months Ended	3 Months Ended	6 Months Ended		0 Months Ended	3 Months Ended		6 Months Ended	0 Months Ended	1 Months Ended		3 Months Ended
	Apr. 17, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Apr. 17, 2014 Other Nonoperating Income (Expense) [Member] Watson Product Disposition [Member]	Jun. 30, 2014 Lidocaine/Prilocaine Topical Cream [Member] Watson Laboratories, Inc. [Member]	Jun. 30, 2013 Lidocaine/Prilocaine Topical Cream [Member] Watson Laboratories, Inc. [Member]	Jun. 30, 2014 Lidocaine/Prilocaine Topical Cream [Member] Watson Laboratories, Inc. [Member]	Jun. 30, 2013 Lidocaine/Prilocaine Topical Cream [Member] Watson Product Disposition [Member]	Jun. 30, 2014 Zioptan [Member] Licensing Agreements [Member]	Jun. 30, 2014 Zioptan [Member]	Jun. 30, 2014 Zioptan [Member]	Jan. 02, 2014 Betimol Acquisition [Member]	Jun. 30, 2014 Betimol [Member] Betimol Acquisition [Member]	Jun. 30, 2014 Betimol [Member] Betimol Acquisition [Member]	Apr. 17, 2014 Marketed Under Abbreviated New Drug Applications [Member] Watson Laboratories, Inc. [Member]	Apr. 17, 2014 Marketed Under a New Drug Application [Member] Watson Laboratories, Inc. [Member]	Apr. 17, 2014 Under Development [Member] Watson Laboratories, Inc. [Member]	Jun. 30, 2014 Before Discount [Member] Betimol Acquisition [Member]	Jun. 30, 2014 Licensing Agreements [Member] Hi-Tech Pharmacal Co., Inc [Member]	Jun. 30, 2014 Customer Relationships [Member] Hi-Tech Pharmacal Co., Inc [Member]	Jun. 30, 2014 Trademarks [Member] Hi-Tech Pharmacal Co., Inc [Member]	May 09, 2014 Term Loan [Member] VersaPharm [Member] JPMorgan [Member]	Apr. 17, 2014 Term Loan [Member] Hi-Tech Pharmacal Co., Inc [Member] JPMorgan [Member]	May 09, 2014 Commitment Fees [Member] VersaPharm [Member]	Jun. 30, 2014 Commitment Fees [Member] VersaPharm [Member]	Jun. 27, 2014 Convertible Debt [Member] Aciex Agreement [Member]	Apr. 17, 2014 Convertible Debt [Member] Aciex Agreement [Member]	Jun. 30, 2014 Convertible Debt [Member]	Jun. 30, 2013 Convertible Debt [Member]	Jun. 30, 2014 Convertible Debt [Member]	Jun. 30, 2013 Convertible Debt [Member]	Jun. 30, 2014 Termination Fee [Member] VersaPharm [Member]	Apr. 17, 2014 Watson Product Disposition [Member] Hi-Tech Pharmacal Co., Inc [Member]	Apr. 17, 2014 Watson Product Disposition [Member]	May 09, 2014 VersaPharm [Member]	Jun. 30, 2014 VersaPharm [Member]	Jun. 30, 2014 VersaPharm [Member]	Apr. 17, 2014 Hi-Tech Pharmacal Co., Inc [Member]	Jun. 30, 2014 Hi-Tech Pharmacal Co., Inc [Member]	Jun. 30, 2014 Hi-Tech Pharmacal Co., Inc [Member]	Mar. 31, 2014 Hi-Tech Pharmacal Co., Inc [Member]	Jan. 02, 2014 Betimol Acquisition [Member]	Jun. 30, 2014 Betimol Acquisition [Member]	Jun. 30, 2014 Betimol Acquisition [Member]	Nov. 15, 2013 Merck Acquisition [Member] Inspire Pharmaceuticals [Member]	Nov. 15, 2013 Merck Acquisition [Member]	Jun. 30, 2014 Merck Acquisition [Member]	Dec. 31, 2013 Merck Acquisition [Member]	Jun. 30, 2014 Merck Acquisition [Member]	Sep. 30, 2011 Aciex Agreement [Member]	Jun. 27, 2014 Aciex Agreement [Member]	Aug. 31, 2011 Aciex Agreement [Member]	Jun. 30, 2014 ECR Pharmaceuticals Divestiture [Member]	Jun. 20, 2014 ECR Pharmaceuticals Divestiture [Member]	Apr. 17, 2014 Hi-Tech Pharmacal Co., Inc [Member]
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) [Line Items]
Payments to Acquire Businesses, Gross	$ 649,600																																						$ 440,000,000						$ 7,500,000		$ 7,500,000
Number of ANDA'S																																						11
Debt Instrument, Face Amount																									445,000,000	600,000,000
Debt Instrument, Fee																											$1.7
Amortization of Financing Costs		2,436,000	207,000	8,590,000	411,000																							500,000			198,000	184,000	392,000	365,000
Business Acquisition, Unrecognized Termination Fee																																			22,000,000
Business Combination, Acquisition Related Costs		20,773,000		21,227,000	519,000																																			1,000,000		19,600,000	20,000,000
Business Combination, Consideration Transferred												11,200,000																													650,000,000						11,500,000		52,800,000		52,800
Business Acquisition, Share Price (in Dollars per share)																																												$ 43.50
Payments to Acquire Businesses, Net of Cash Acquired																																									44,600,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)																																																										$ 0.01
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																																																										$ 43.50
Business Acquisition, Goodwill, Expected Tax Deductible Amount																																										18,500,000	18,500,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life																						15 years 255 days	1 year	9 years																			15 years 219 days
Business Acquisition, Pro Forma Revenue																																										51,500,000
Number of Products Divested																		3	1	1																																					3
Disposal Group, Including Discontinued Operation, Revenue								300,000	1,400,000	1,500,000	2,400,000																																													3,400,000
Business Acquisition, Percentage of Voting Interests Acquired																																									50.00%
Proceeds from Divestiture of Businesses																																					16,800,000
Gain (Loss) on Disposition of Business							9,000,000																																																	900
Duration of Production																																				2 years											2 years
Disposal Group, Including Discontinued Operation, Consideration																																																								41,000	41,000,000
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest				(0.5)																																																				(0.5)
Product Acquisition Transitional Period														2 years
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual													3,800,000			1,600,000	4,400,000																																	6,400,000		15,800,000
Business Acquisition, Consideration, Sales Multiplier															1.5																														1.5
Business Acquisition, Duration Following the First Year Post-Acquisition																																															60 days
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High																																														2,000,000	2,000,000
Business Combination, Contingent Consideration Arrangements, Triggering Sales Amount																																														14,000,000	14,000,000
Business Combination, Contingent Consideration Arrangements, Triggering Duration																																															1 year
Business Combination, Contingent Consideration Arrangements, Triggering Duration Span																																															5 years
Business Combination, Contingent Consideration, Liability																					4,500,000																									4,000,000	4,000,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				100,000																																										100,000
Business Combination, Number of Products																																																3	2
Finite-Lived Intangible Assets, Remaining Amortization Period																																																				15 years
Payments to Acquire Additional Interest in Subsidiaries																																																					2,000,000		8,000,000
Payments for (Proceeds from) Other Investing Activities																													400,000	400,000
Cost Method Investments		$ 10,965,000		$ 10,965,000		$ 10,006,000																																																$ 10,800,000
Business Acquisition Percentage Not Exceeded Of Voting Interests Acquired																																																						20.00%